- Professor, Medical Oncology, University of Nantes (France) and Integrated Centers of Oncology ICO Rene Gauducheau Cancer Nantes (France)
Dr. Jean-Yves Douillard received his medical training at the University of Nantes Medical School in Nantes, France. During his training, he developed an interest in tumor immunology and obtained a fellowship from the French Ministry of Health and the US National Institutes of Health John E. Fogarty International Center for Advanced Study in the Health Sciences. He spent 2 years as a visiting fellow at the National Cancer Institute’s Laboratory of Immunodiagnosis, where he was involved in the production and characterization of monoclonal antibodies against natural killer cells. Dr. Douillard returned to France in 1981 and became an Assistant Professor in Medical Oncology at the University of Nantes, where he specialized in lung cancer, gastrointestinal oncology, and biologic therapies, including the use of monoclonal antibodies in human tumors. He later worked for 2 years as a visiting scientist at the FDA’s Center for Biologics Evaluation and Research, where he was involved in monoclonal antibody therapy. Dr. Douillard received his PhD in 1993.
Dr. Douillard has participated in clinical trials mostly for lung cancer and GI tumors, and has investigated numerous new drugs, including vinorelbine, irinotecan, docetaxel, paclitaxel, and gemcitabine. He also has investigated targeted therapies such as gefitinib, erlotinib, farnesyltransferase inhibitors, Raf kinases inhibitors, antiangiogenic molecules, and monoclonal antibodies.
Dr. Douillard has published numerous articles in various scientific journals, including The Lancet, The New England Journal of Medicine, Journal of Clinical Oncology, The Lancet Oncology, British Journal of Cancer, Cancer Research, European Journal of Cancer, Annals of Oncology, and the Journal of Thoracic Oncology. He was a member of the editorial boards of the Journal of Clinical Oncology and Bulletin du Cancer. He currently serves on the editorial board of Hybridoma and is the International Editor of Clinical Colorectal Cancer. Dr. Douillard is a member of the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), International Association for the Study of Lung Cancer (IASLC), American Association for Cancer Research (AACR), and Intergroupe Francophone de Cancérologie Thoracique (IFCT).
Professor, Medical Oncology, University of Nantes (France); Director of Clinical and Translational Research, Rene Gauducheau Cancer Center Nantes (France)
University of Nantes, France, MD
University of Nantes, France, PhD
Resident, Centre Hospitalier Universitaire de Nantes, France
Fellow, French Ministry of Health and US National Institutes of Health John E. Fogarty
International Center for Advanced Study in the Health Sciences
Lung cancer, gastrointestinal cancer, monoclonal antibody therapy
Recent Contributions to PracticeUpdate:
- ESMO Interview: Lung Cancer Studies—Part 3
- ESMO Interview: Lung Cancer Studies—Part 2
- ESMO Interview: Lung Cancer Studies—Part 1
- Dr. Jean-Yves Douillard’s ESMO 2014 Recommendations in Lung Cancer
- Thoracic Radiotherapy in Extensive-Stage SCLC Improved Survival Outcomes
- Cisplatin- vs Carboplatin-Based Chemoradiotherapy in Elderly Patients With Non–Small Cell Lung Cancer
- Fewer Cycles of Platinum-Based Chemotherapy May Be Adequate in NSCLC
- Activity of FOLFIRI Plus Cetuximab According to Extended Gene Mutation Status
- Dr. Jean-Yves Douillard’s ASCO 2014 LBA Pick for Lung Cancer
- Dr. Jean-Yves Douillard’s 2014 ASCO Abstract Recommendations—Lung Cancer
Transformative Moments in Oncology: Curative Combination Therapy for Cancer
Dacomitinib as First-Line Treatment in Selected Advanced NSCLC
Gemcitabine vs Gemcitabine Plus Sunitinib in Advanced Pancreatic Cancer
Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival
Standard or Short-Course Irradiation Plus Temozolomide for Elderly Patients With Glioblastoma
Paclitaxel, Bevacizumab, and Capecitabine as First-Line Treatment in Breast Cancer
Efficacy of Bevacizumab Plus 5-FU/Streptozocin in Metastatic Pancreatic Endocrine Tumors
3-Day Bleomycin, Etoposide, and Cisplatin Safe and Effective in Malignant Ovarian Germ Cell Tumors
Safety and Efficacy of Treatment Regimens for Stage III Colon Cancer
Personalized Chemotherapy Based on Tumor Marker Decline
Our Advisory and Editorial Boards are comprised of physician editors and world-renowned experts.